公开(公告)号：US09610251B2

公开(公告)日：2017-04-04

申请号：US13665147

申请日：2012-10-31

Applicant: Resverlogix Corp.

Inventor： Narmada R. Shenoy

IPC: A61P35/00 ,  A61K9/48 ,  A61K31/517

CPC classification number: A61K31/517 ,  A61K9/1611 ,  A61K9/1617 ,  A61K9/1652 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866

Abstract: The present disclosure relates to novel solid pharmaceutical formulations and process for their preparation. The present disclosure also provides, in part, methods of using the pharmaceutical formulations for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

公开(公告)号：US20120015905A1

公开(公告)日：2012-01-19

申请号：US13243776

申请日：2011-09-23

Applicant: Henrik C. Hansen

Inventor： Henrik C. Hansen

IPC: A61K31/695 ,  A61K31/5377 ,  A61P3/00 ,  A61P9/00 ,  A61P3/06 ,  A61K31/517 ,  A61K31/519

CPC classification number: A61K31/517 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/47 ,  A61K31/472 ,  A61K31/496 ,  A61K31/497 ,  A61K31/519 ,  A61K31/535 ,  A61K31/5377 ,  A61K31/54 ,  A61K31/695 ,  A61L29/16 ,  A61L31/16 ,  A61L2300/204 ,  A61L2300/606 ,  A61L2420/00 ,  C07D217/24 ,  C07D239/91 ,  C07D279/02 ,  C07D401/04 ,  C07D403/12 ,  C07D405/04 ,  C07D471/04 ,  C07F7/1804

Abstract: The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

Abstract translation: 本公开涉及可用于调节载脂蛋白AI（ApoA-I）的表达的化合物及其用于治疗和预防心血管疾病和相关疾病状态的用途，包括胆固醇或脂质相关疾病，例如， 例如动脉粥样硬化。

公开(公告)号：US20230398137A1

公开(公告)日：2023-12-14

申请号：US18032876

申请日：2021-10-29

Applicant: Resverlogix Corp.

Inventor： Kenneth Eugene LEBIODA ,  Christopher Ross Armstrong HALLIDAY ,  Aziz Naeem KHAN

IPC: A61K31/7048 ,  A61K31/517 ,  A61K31/7034 ,  A61P3/08

CPC classification number: A61K31/7048 ,  A61K31/517 ,  A61K31/7034 ,  A61P3/08

Abstract: Described herein are methods for lowering glycated hemoglobin (HbA1c) level to treat and/or prevent a diabetes-related disease or disorder by administering to a subject in need thereof, a combination of a sodium-glucose transport protein 2 (SGLT2) inhibitor and a compound of Formula I or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein the variables of Formula I are as defined herein.

公开(公告)号：US10111885B2

公开(公告)日：2018-10-30

申请号：US15066513

申请日：2016-03-10

Applicant: Resverlogix Corp.

Inventor： Ewelina B. Kulikowski ,  Dean E. Gilham ,  Sylwia Wasiak ,  Christopher R. A. Halliday ,  Laura M. Tsujikawa

IPC: A61K31/551 ,  A61K31/517

Abstract: The invention comprises methods of modulating the complement cascade in a mammal and for treating and/or preventing diseases and disorders associated with the complement pathway by administering a compound of Formula I or Formula II, such as, for example, 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20170119767A1

公开(公告)日：2017-05-04

申请号：US15408814

申请日：2017-01-18

Applicant: Resverlogix Corp.

Inventor： Narmada R. Shenoy

IPC: A61K31/517 ,  A61K9/48 ,  A61K9/16

CPC classification number: A61K31/517 ,  A61K9/1611 ,  A61K9/1617 ,  A61K9/1652 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866

Abstract: The present disclosure relates to novel solid pharmaceutical formulations and process for their preparation. The present disclosure also provides, in part, methods of using the pharmaceutical formulations for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

公开(公告)号：US20160137613A1

公开(公告)日：2016-05-19

申请号：US14942009

申请日：2015-11-16

Applicant: Henrik C. Hansen

Inventor： Henrik C. Hansen

IPC: C07D239/91 ,  C07D403/10 ,  C07D401/04 ,  C07D409/12 ,  C07D401/12 ,  C07D401/14 ,  C07D401/10 ,  C07D471/04

CPC classification number: C07D239/91 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/551 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D409/10 ,  C07D409/12 ,  C07D471/04

Abstract: Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation.

Abstract translation: 公开了可用于调节白细胞介素-6（IL-6）和/或血管细胞粘附分子-1（VCAM-1）的表达的新型化合物及其在治疗和/或预防心血管和炎症疾病中的用途 和相关疾病状态，例如动脉粥样硬化，哮喘，关节炎，癌症，多发性硬化，牛皮癣和炎症性肠病以及自身免疫性疾病。 还公开了包含新化合物的组合物，以及它们的制备方法。

公开(公告)号：US08952021B2

公开(公告)日：2015-02-10

申请号：US13143757

申请日：2010-01-08

Applicant: Henrik C. Hansen

Inventor： Henrik C. Hansen

IPC: A61K31/517 ,  A61K31/519 ,  C07D239/91 ,  C07D401/04 ,  C07D403/04 ,  C07D471/04

CPC classification number: C07D239/91 ,  A61K31/517 ,  C07D401/04 ,  C07D403/04 ,  C07D471/04

Abstract: Disclosed are novel compounds that are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis. Also disclosed are pharmaceutical compositions comprising the novel compounds. Formula (I)

Abstract translation: 公开了可用于调节载脂蛋白AI（ApoA-I）的表达的新型化合物及其用于治疗和预防心血管疾病和相关疾病状态的用途，包括胆固醇或脂质相关疾病，例如 ，动脉粥样硬化。 还公开了包含新化合物的药物组合物。 式（I）

公开(公告)号：US08114995B2

公开(公告)日：2012-02-14

申请号：US12490877

申请日：2009-06-24

Applicant: Henrik C. Hansen ,  Shubham P. Chopade ,  Janakiram R. Citineni ,  Robert P. Short ,  George P. Yiannikouros

Inventor： Henrik C. Hansen ,  Shubham P. Chopade ,  Janakiram R. Citineni ,  Robert P. Short ,  George P. Yiannikouros

IPC: C07D239/91

CPC classification number: C07D239/91

Abstract: The present disclosure relates to methods for preparing compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and in the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

Abstract translation: 本公开涉及制备化合物的方法，其可用于调节载脂蛋白AI（ApoA-I）的表达，以及用于治疗和预防心血管疾病和相关疾病状态，包括胆固醇或脂质相关疾病，例如 例如，动脉粥样硬化。

公开(公告)号：US20100004448A1

公开(公告)日：2010-01-07

申请号：US12490877

申请日：2009-06-24

Applicant: Henrik C. Hansen ,  Shubham P. Chopade ,  Janakiram R. Citineni ,  Robert P. Short ,  George P. Yiannikouros

Inventor： Henrik C. Hansen ,  Shubham P. Chopade ,  Janakiram R. Citineni ,  Robert P. Short ,  George P. Yiannikouros

IPC: C07D239/88 ,  A61P9/10

CPC classification number: C07D239/91

Abstract: The present disclosure relates to methods for preparing compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and in the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

Abstract translation: 本公开涉及制备化合物的方法，其可用于调节载脂蛋白AI（ApoA-I）的表达，以及用于治疗和预防心血管疾病和相关疾病状态，包括胆固醇或脂质相关疾病，例如 例如，动脉粥样硬化。

公开(公告)号：US20230381178A1

公开(公告)日：2023-11-30

申请号：US18032450

申请日：2021-10-29

Applicant: Resverlogix Corp.

Inventor： Kenneth Eugene LEBIODA ,  Christopher Ross Armstrong HALLIDAY ,  Aziz Naeem KHAN

IPC: A61K31/517 ,  A61K31/7048 ,  A61K31/7042 ,  A61K31/70 ,  A61P13/12

CPC classification number: A61K31/517 ,  A61K31/7048 ,  A61K31/7042 ,  A61K31/70 ,  A61P13/12

Abstract: Described herein are methods for treating and/or preventing a kidney disease or an associated disorder as measured by an increase in estimated glomerular filtration rate (eGFR) by administering to a subject in need thereof, a combination of a sodium-glucose transport protein 2 (SGLT2) inhibitor and a compound of Formula I or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein the variables of Formula I are as defined herein.